Travere Therapeutics price target raised to $47 from $45 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...
Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently
We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc.
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its target price hoisted by equities researchers at Canaccord Genuity Group from $22.00 to $45.00 in a research report issued on ...